Clinical trials: Liver Cirrhosis, Biliary
Primary Sclerosing Cholangitis
Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC), although uncommon, is a devastating and insidiously progressive liver disease, resulting from advancing inflammation, fibrosis and obliteration of the bile ducts in the liver, leading to…
- Trial name
- NCT01088607
- Testing
- ursodeoxycholic acid (UDCA)
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Tennessee
Acute Liver Failure, Mitochondrial Diseases
Longitudinal Study of Mitochondrial Hepatopathies
The specific aims of this study are (1) to determine the clinical phenotypes and natural history of hepatic RC and FAO disorders, (2) to determine the correlation between genotype and phenotype, (3) to determine if circulating…
- Conditions
- Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial
- Trial name
- MITOHEP (NCT01148550)
- Where
- 16 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- Arbor Research Collaborative for Health
Primary Biliary Cirrhosis
Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis
The University of Michigan is conducting a study investigating a potential new treatment aimed at slowing/halting progression of primary biliary cirrhosis.
- Trial name
- NCT00805805
- Testing
- Tetrathiomolybdate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- George Brewer
Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Biobank for Cholestatic Liver Diseases.
This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis…
- Conditions
- Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
- Trial name
- NCT03445585
- Where
- United States
- Volunteers
- 9,150 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis
Canadian Network for Autoimmune Liver Disease
CaNAL is a longitudinal observational cohort study of patients diagnosed with Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH), or overlap syndrome.
- Conditions
- Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome
- Trial name
- CaNAL (NCT03569826)
- Testing
- Observational; no intervention
- Where
- 15 sites in Canada
- Volunteers
- 2,500 people
- Sponsor
- University Health Network, Toronto
Hepatitis Autoimmune Disease, Primary Biliary Cholangitis (PBC)
Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)
The purpose of the registry is to know the status of primary biliary colgantis, autoimmune hepatitis, primary sclerosing cholagitis and genetic cholestatic diseases in Spain.
- Conditions
- Hepatitis Autoimmune Disease, Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Cholestatic Genetic Diseases
- Trial name
- ColHai (NCT06767605)
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Asociación Española para el Estudio del Hígado
Primary Biliary Cholangitis (PBC)
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
A phase II study to evaluate safety, tolerability and efficacy of CS0159 in patients with PBC (Primary Biliary Cholangitis).
- Trial name
- NCT05896124
- Testing
- 2mg CS0159
- Where
- 16 sites in China
- Volunteers
- 75 people
- Sponsor
- Cascade Pharmaceuticals, Inc
Primary Biliary Cholangitis (PBC)
A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis
This study is a prospective, single center, randomized controlled, exploratory clinical trial aimed at evaluating the efficacy and safety of fenofibrate in newly diagnosed PBC subjects.
- Trial name
- NCT06591455
- Testing
- Fenofibrate, UDCA (Ursodeoxycholic acid)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Han Ying
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Primary Biliary Cirrhosis
Pentoxifylline for Primary Biliary Cirrhosis
Primary biliary cirrhosis (PBC) is cholestatic liver disease characterized by progressive destruction of small bile ducts within the liver that can lead to end stage liver disease and all its complications.
- Trial name
- NCT01249092
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Cleveland Clinic
Primary Biliary Cirrhosis
Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis
The purpose of this study is to determine if abatacept (Orencia) is effective in patients with primary biliary cirrhosis who do not respond adequately to standard treatment with ursodeoxycholic acid (UDCA, Urso, Ursodiol…
- Trial name
- PBC (NCT02078882)
- Testing
- abatacept
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Christopher Bowlus, MD
Primary Biliary Cholangitis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
The goal of this clinical study is to learn more about the study drug, seladelpar, and its effects on clinical outcomes in participants with primary biliary cholangitis (PBC) and compensated cirrhosis.
- Trial name
- AFFIRM (NCT06051617)
- Testing
- Seladelpar
- Where
- 218 sites in United States, Argentina and 27 more
- Volunteers
- 402 people
- Sponsor
- Gilead Sciences
Pruritus, Liver Cirrhosis, Biliary
Treatment of Cholestatic Pruritus With Sertraline
The goal of this study is to find an effective and well-tolerated medical therapy for itching due to liver disease. Persons with primary biliary cirrhosis or chronic hepatitis C are currently being enrolled in the study.
- Conditions
- Pruritus, Liver Cirrhosis, Biliary, Hepatitis C
- Trial name
- NCT00058903
- Testing
- sertraline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary Biliary Cholangitis (PBC)
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a…
- Trial name
- ELFIDENCE (NCT06016842)
- Testing
- Elafibranor
- Where
- 198 sites in United States, Argentina and 26 more
- Volunteers
- 276 people
- Sponsor
- Ipsen
Primary Biliary Cholangitis (PBC)
Probiotics in PBC Patients of Poor Response to UDCA
The safety and efficacy of probiotics in primary biliary cholangitis (PBC) patients with poor ursodeoxycholic acid (UDCA) response.
- Trial name
- NCT03521297
- Testing
- Probiotic
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Primary Biliary Cholangitis
Combination Antiretroviral Therapy (cART) for PBC
Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to Ursodeoxycholic Acid (UDCA).
- Trial name
- NCT03954327
- Testing
- Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Raltegravir
- Where
- 6 sites in Canada
- Volunteers
- 37 people
- Sponsor
- University of Alberta
Liver Cirrhosis, Biliary
Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis
OBJECTIVES: I. Compare the effects of ursodiol (ursodeoxycholic acid), with and without methotrexate, on pruritus, incapacitation index, and serum markers of activity and severity in patients with primary biliary cirrhosis. II.
- Trial name
- NCT00004784
- Testing
- methotrexate, ursodiol
- Volunteers
- 315 people
- Sponsor
- National Center for Research Resources (NCRR)
Biliary Cirrhosis, Primary
Family Studies in Primary Biliary Cirrhosis (PBC)
Primary biliary cirrhosis (PBC) is a chronic liver disease primarily affecting middle age women. It is characterized by immune-mediated damage to cells lining the tiny bile ducts within the liver.
- Trial name
- NCT00242125
- Where
- Canada
- Volunteers
- 3,000 people
- Sponsor
- University Health Network, Toronto
Cirrhosis, Biliary Atresia
Predictive Models of Hepatic Decompensation and Survival Outcomes in Pediatric Patients With Cirrhosis
The aim of this study was to developed and validated models to predict hepatic decompensation and survivals in pediatric patients with cirrhosis and compared these models with currently available models.
- Conditions
- Cirrhosis, Biliary Atresia, Choledochal Cyst, Primary Sclerosing Cholangitis
- Trial name
- NCT05181332
- Testing
- Prediction model
- Where
- China
- Volunteers
- 400 people
- Sponsor
- West China Hospital
Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC)
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT).
- Conditions
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
- Trial name
- NCT07678645
- Testing
- Upadacitinib 15 MG
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RenJi Hospital